---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-002622"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:32:07.946908+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants BioNexus Gene Lab 180-day extension to meet $1 bid price rule through Nov 4, 2024

## Summary
- Initial bid price deficiency notice received Nov 6, 2023; original 180-day cure period expired May 6, 2024.
- On May 8, 2024, Nasdaq granted additional 180-day extension to regain compliance, now due by Nov 4, 2024.
- To cure, closing bid price must be at least $1.00 for a minimum of 10 consecutive business days.
- If not cured, Nasdaq will delist; company may request hearing before Nasdaq Hearings Panel to stay delisting.
- Company states it will use reasonable efforts but cannot assure it will regain compliance.

## SEC filing metadata
- accession: 0001477932-24-002622
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793224002622/0001477932-24-002622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793224002622/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-002622
- JSON: https://secwatch.observer/filing/0001477932-24-002622.json
- Plain text: https://secwatch.observer/filing/0001477932-24-002622.txt

## Key facts
- Listing & Compliance Notices
  BioNexus Gene Lab Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: May 8, 2024, the Company received notification from NASDAQ that, after an analysis of the requirements under Nasdaq Listing Rule 5810 (c)(3)(A), the Staff determined that the Company is eligible for an additional 180 calendar day extension period (the “ Additional Period ”), or until November 4, 2024. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event that the Company is not able to cure the bid price deficiency during the Additional
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737523/000147793224002622/0001477932-24-002622-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.